State Street Corp Has $21.59 Million Stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

State Street Corp grew its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 2.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,945,060 shares of the biotechnology company's stock after buying an additional 64,949 shares during the quarter. State Street Corp owned 2.06% of Aurinia Pharmaceuticals worth $21,587,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Banque Cantonale Vaudoise raised its position in Aurinia Pharmaceuticals by 126.6% in the second quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 5,410 shares in the last quarter. CWM LLC grew its stake in shares of Aurinia Pharmaceuticals by 247.7% in the 3rd quarter. CWM LLC now owns 11,483 shares of the biotechnology company's stock valued at $84,000 after purchasing an additional 8,180 shares during the period. FMR LLC raised its holdings in shares of Aurinia Pharmaceuticals by 44.8% in the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company's stock worth $93,000 after buying an additional 3,919 shares in the last quarter. B. Riley Wealth Advisors Inc. bought a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter worth approximately $84,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Aurinia Pharmaceuticals by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company's stock valued at $202,000 after buying an additional 10,700 shares in the last quarter. 36.83% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of the firm's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $8.43, for a total value of $38,415.51. Following the transaction, the director now owns 13,356 shares of the company's stock, valued at approximately $112,591.08. This trade represents a 25.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on AUPH. StockNews.com lowered Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Friday, December 13th. HC Wainwright reiterated a "buy" rating and set a $13.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a research report on Monday, September 16th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $10.00.

Aurinia Pharmaceuticals Price Performance

Shares of AUPH stock traded up $0.03 during trading hours on Tuesday, hitting $8.98. 487,429 shares of the company's stock were exchanged, compared to its average volume of 1,593,346. The stock's 50-day moving average is $8.31 and its 200-day moving average is $6.92. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.71 and a 52 week high of $10.67. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -59.86 and a beta of 1.41.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.